Ensuring equity in the era of HLA-restricted cancer therapeutics

In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the human leucocyte antigen (HLA) A*0201 allele. This approval generated significant excitement, given the relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Smithy, James W, Blouin, Amanda, Diamond, Lisa C, Postow, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710357/
https://www.ncbi.nlm.nih.gov/pubmed/36442912
http://dx.doi.org/10.1136/jitc-2022-005600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710357/
https://www.ncbi.nlm.nih.gov/pubmed/36442912
http://dx.doi.org/10.1136/jitc-2022-005600

Ejemplares similares